Advertisement

European Radiology

, Volume 26, Issue 10, pp 3728–3736 | Cite as

Hypovascular hypointense nodules on hepatobiliary phase without T2 hyperintensity on gadoxetic acid-enhanced MR images in patients with chronic liver disease: long-term outcomes and risk factors for hypervascular transformation

  • Yong Seek Kim
  • Ji Soo SongEmail author
  • Hyun Kyung Lee
  • Young Min Han
Magnetic Resonance

Abstract

Purpose

To evaluate the long-term outcomes and imaging features associated with hypervascularization of hypovascular nodules that show T2 iso-/hypointensity and hypointensity on hepatobiliary phase (HBP) of gadoxetic acid-enhanced magnetic resonance (MR) images in patients with chronic liver disease.

Materials and methods

Sixty patients and 114 nodules, which were hypovascular and iso-/hypointense on T2-weighted images and hypointense on HBP of gadoxetic acid-enhanced MRI, were included. We evaluated the effect of baseline clinical features, baseline MR features and growth rate on subsequent hypervascularization.

Results

Twenty-seven nodules in 21 patients transformed to hypervascular hepatocellular carcinoma (HCC). Using multivariate Cox analysis, T1 hyperintensity (hazard ratio [HR] = 2.69, P = 0.021), previous history of HCC (HR = 2.64, P = 0.021), and initial nodule size (HR = 1.09, P = 0.046) were identified to be associated with hypervascularization. The growth rate of nodules was a more powerful determinant of subsequent hypervascularization than baseline clinical and MR features. At long-term follow-up after >3 years, only one nodule with T1 isointensity showed hypervascularization.

Conclusion

Careful follow-up or diagnostic procedures, such as biopsy, should be considered for up to 3 years after detection of hypointense nodules on HBP with T1 hyperintensity or a higher growth rate.

Key Points

T1 hyperintensity is a baseline MR predictive factor for subsequent hypervascularization.

A higher growth rate is a more powerful determinant of subsequent hypervascularization.

Management of patients with these predictive factors requires more attention.

Keywords

Magnetic resonance imaging Gadoxetic acid Hepatocellular carcinoma Hypervascular transformation Hepatocarcinogenesis 

Abbreviations

HBP

Hepatobiliary phase

HCC

Hepatocellular carcinoma

MR

Magentic resonance

TACE

Transarterial chemoembolization

Notes

Acknowledgements

The scientific guarantor of this publication is Ji Soo Song. The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article. This paper was supported by the Fund of Biomedical Research Institute, Chonbuk National University Hospital. No complex statistical methods were necessary for this paper. Institutional Review Board approval was obtained. Written informed consent was waived by the Institutional Review Board. No subjects or cohorts have been previously reported. Methodology: retrospective, diagnostic or prognostic study, performed at one institution.

References

  1. 1.
    Choi JY, Lee JM, Sirlin CB (2014) CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. Radiology 272:635–654CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Haradome H, Grazioli L, Tinti R, Morone M, Motosugi U, Sano K et al (2011) Additional value of gadoxetic acid-DTPA-enhanced hepatobiliary phase MR imaging in the diagnosis of early-stage hepatocellular carcinoma: comparison with dynamic triple-phase multidetector CT imaging. J Magn Reson Imaging 34:69–78CrossRefPubMedGoogle Scholar
  3. 3.
    Ahn SS, Kim M-J, Lim JS, H-s H, Chung YE, Choi J-Y (2010) Added value of gadoxetic acid–enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology 255:459–466CrossRefPubMedGoogle Scholar
  4. 4.
    Park YN (2011) Update on precursor and early lesions of hepatocellular carcinomas. Arch Pathol Lab Med 135:704–715CrossRefPubMedGoogle Scholar
  5. 5.
    Motosugi U, Ichikawa T, Sano K, Sou H, Onohara K, Muhi A et al (2011) Outcome of hypovascular hepatic nodules revealing no gadoxetic acid uptake in patients with chronic liver disease. J Magn Reson Imaging 34:88–94CrossRefPubMedGoogle Scholar
  6. 6.
    Kumada T, Toyoda H, Tada T, Sone Y, Fujimori M, Ogawa S et al (2011) Evolution of hypointense hepatocellular nodules observed only in the hepatobiliary phase of gadoxetate disodium–enhanced MRI. Am J Roentgenol 197:58–63CrossRefGoogle Scholar
  7. 7.
    Akai H, Matsuda I, Kiryu S, Tajima T, Takao H, Watanabe Y et al (2012) Fate of hypointense lesions on Gd-EOB-DTPA-enhanced magnetic resonance imaging. Eur J Radiol 81:2973–2977CrossRefPubMedGoogle Scholar
  8. 8.
    Kobayashi S, Matsui O, Gabata T, Koda W, Minami T, Ryu Y et al (2012) Relationship between signal intensity on hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (Gd-EOB-DTPA)-enhanced MR imaging and prognosis of borderline lesions of hepatocellular carcinoma. Eur J Radiol 81:3002–3009CrossRefPubMedGoogle Scholar
  9. 9.
    Hyodo T, Murakami T, Imai Y, Okada M, Hori M, Kagawa Y et al (2013) Hypovascular nodules in patients with chronic liver disease: risk factors for development of hypervascular hepatocellular carcinoma. Radiology 266:480–490CrossRefPubMedGoogle Scholar
  10. 10.
    Kim YK, Lee WJ, Park MJ, Kim SH, Rhim H, Choi D (2012) Hypovascular hypointense nodules on hepatobiliary phase gadoxetic acid–enhanced MR images in patients with cirrhosis: potential of DW imaging in predicting progression to hypervascular HCC. Radiology 265:104–114CrossRefPubMedGoogle Scholar
  11. 11.
    Joishi D, Ueno A, Tanimoto A, Okuda S, Masugi Y, Emoto K et al (2013) Natural course of hypovascular nodules detected on gadoxetic acid-enhanced MR imaging: presence of fat is a risk factor for hypervascularization. Magn Reson Med Sci 12:281–287CrossRefPubMedGoogle Scholar
  12. 12.
    Choi J-Y, Lee J-M, Sirlin CB (2014) CT and MR Imaging Diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. Radiology 273:30–50CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Inchingolo R, De Gaetano AM, Curione D, Ciresa M, Miele L, Pompili M et al (2015) Role of diffusion-weighted imaging, apparent diffusion coefficient and correlation with hepatobiliary phase findings in the differentiation of hepatocellular carcinoma from dysplastic nodules in cirrhotic liver. Eur Radiol 25:1087–1096CrossRefPubMedGoogle Scholar
  14. 14.
    Willatt JM, Hussain HK, Adusumilli S, Marrero JA (2008) MR imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology 247:311–330CrossRefPubMedGoogle Scholar
  15. 15.
    Hwang J, Kim YK, Jeong WK, Choi D, Rhim H, Lee WJ (2015) Nonhypervascular hypointense nodules at gadoxetic acid-enhanced MR imaging in chronic liver disease: diffusion-weighted imaging for characterization. Radiology 276:137–146CrossRefPubMedGoogle Scholar
  16. 16.
    Schwartz M (1961) A biomathematical approach to clinical tumor growth. Cancer 14:1272–1294CrossRefPubMedGoogle Scholar
  17. 17.
    Xu PJ, Yan FH, Wang JH, Shan Y, Ji Y, Chen CZ (2010) Contribution of diffusion-weighted magnetic resonance imaging in the characterization of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver. J Comput Assist Tomogr 34:506–512CrossRefPubMedGoogle Scholar
  18. 18.
    Golfieri R, Renzulli M, Lucidi V, Corcioni B, Trevisani F, Bolondi L (2011) Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to Dynamic MRI in the detection of hypovascular small (</= 2 cm) HCC in cirrhosis. Eur Radiol 21:1233–1242CrossRefPubMedGoogle Scholar
  19. 19.
    Kim T, Baron RL, Nalesnik MA (2000) Infarcted regenerative nodules in cirrhosis: CT and MR imaging findings with pathologic correlation. AJR Am J Roentgenol 175:1121–1125CrossRefPubMedGoogle Scholar
  20. 20.
    Lee S, Choi D, Jeong WK, Kim YK, Lim JH, Choi MS et al (2015) Frequency, CT findings, and fate of multiple infarcted regenerative nodules in liver cirrhosis after variceal bleeding or septic shock. Abdom Imaging 40:835–842CrossRefPubMedGoogle Scholar
  21. 21.
    Hanna RF, Aguirre DA, Kased N, Emery SC, Peterson MR, Sirlin CB (2008) Cirrhosis-associated hepatocellular nodules: correlation of histopathologic and MR imaging features. Radiographics 28:747–769CrossRefPubMedGoogle Scholar
  22. 22.
    Martin J, Puig J, Darnell A, Donoso L (2002) Magnetic resonance of focal liver lesions in hepatic cirrhosis and chronic hepatitis. Semin Ultrasound CT MR 23:62–78CrossRefPubMedGoogle Scholar
  23. 23.
    Krinsky GA, Israel G (2003) Nondysplastic nodules that are hyperintense on T1-weighted gradient-echo MR imaging: frequency in cirrhotic patients undergoing transplantation. AJR Am J Roentgenol 180:1023–1027CrossRefPubMedGoogle Scholar
  24. 24.
    Earls JP, Theise ND, Weinreb JC, DeCorato DR, Krinsky GA, Rofsky NM et al (1996) Dysplastic nodules and hepatocellular carcinoma: thin-section MR imaging of explanted cirrhotic livers with pathologic correlation. Radiology 201:207–214CrossRefPubMedGoogle Scholar
  25. 25.
    Higaki A, Ito K, Tamada T, Teruki S, Yamamoto A, Higashi H et al (2013) High-risk nodules detected in the hepatobiliary phase of Gd-EOB-DTPA-enhanced MR imaging in cirrhosis or chronic hepatitis: incidence and predictive factors for hypervascular transformation, preliminary results. J Magn Reson Imaging 37:1377–1383CrossRefPubMedGoogle Scholar
  26. 26.
    Higaki A, Ito K, Tamada T, Sone T, Kanki A, Noda Y et al (2014) Prognosis of small hepatocellular nodules detected only at the hepatobiliary phase of Gd-EOB-DTPA-enhanced MR imaging as hypointensity in cirrhosis or chronic hepatitis. Eur Radiol 24:2476–2481CrossRefPubMedGoogle Scholar

Copyright information

© European Society of Radiology 2015

Authors and Affiliations

  • Yong Seek Kim
    • 1
  • Ji Soo Song
    • 1
    • 2
    Email author
  • Hyun Kyung Lee
    • 1
    • 2
  • Young Min Han
    • 1
    • 2
  1. 1.Department of RadiologyChonbuk National University Medical School and HospitalJeonju-siKorea
  2. 2.Research Institute of Clinical MedicineChonbuk National University–Biomedical Research Institute of Chonbuk National University HospitalChonbukKorea

Personalised recommendations